Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Special Issues
2021 Oncology Drug Coding and Updates
2021 Oncology Drug Coding and Updates
A Valuable Resource for Oncology Practices
By
Dawn Holcombe, MBA, FACMPE, ACHE
We are pleased to present this 2021 Oncology Drug Coding and Updates special feature, designed to provide you with helpful information on the topic of oncology drug coding and important details on some of the drugs now available to treat patients with cancer. The COVID-19 pandemic led to many changes in patient care and treatment choices for oncology practices. Flexibility and innovation regarding both oral and infused/injected drugs became key to ensuring patient access to necessary treatments.
Read More ›
Drugs Frequently Used in the Treatment of Cancer and Their Associated Codes and Pricing
The following tables of frequently used oncology drugs are intended to assist practice managers, other healthcare providers, and payers in the proper use of coding and billing information associated with the treatment of their patients.
Read More ›
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
By
Loretta Fala
Drug Updates
Ovarian cancer—including epithelial cancer, fallopian tube cancer, and primary peritoneal cancer—often affects women aged 55 to 64 years, with nearly 70% of all cases occurring in women aged ≥45 years. In 2020, an estimated 21,750 women will be newly diagnosed with ovarian cancer, and approximately 13,940 women will die from this disease in the United States.
Read More ›
Tabrecta (Capmatinib) Approved for Patients with Metastatic NSCLC and MET Exon 14 Skipping Mutation
By
Loretta Fala
Drug Updates
Lung and bronchus cancer is the second most prevalent form of cancer in the United States.
1
Representing 12.7% of all new cancer cases, lung cancer was diagnosed in 228,820 individuals in 2020. It is the leading cause of cancer-related mortality in men and women, accounting for 22.4% of all cancer deaths.
Read More ›
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
By
Loretta Fala
Drug Updates
Epithelioid sarcoma is a rare subtype of soft-tissue sarcoma that most often occurs in the soft tissue of the fingers, hands, and forearms, but that can occur in other areas of the body. In 2005 in the United States, the incidence of epithelioid sarcoma was approximately 0.04 cases per 100,000 people. Epithelioid sarcoma predominantly affects young adults; however, it can affect individuals at any age and is more prevalent in males than in females. Characterized by slow tumor growth and benign manifestations at early stages, epithelioid sarcoma can be challenging to diagnose.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes